Biomarker for BOS response after allo-HCT

Inamoto I, Martin PJ, Onstad LE, et al. Relevance of Plasma Matrix Metalloproteinase-9 for Bronchiolitis Obliterans Syndrome After Allogeneic Hematopoietic Cell Transplantation. Transplantation and Cellular Therapy. 2021; 27 (9): 759 (doi: 10.1016/j.jtct.2021.06.006).

The biomarker, matrix metalloproteinase-9 (MMP-9), may be a relevant biomarker at diagnosis of bronchiolitis obliterans syndrome (BOS) after allogeneic hematopoietic cell transplantation (HCT), a new study reports. This is one of several plasma proteins identified as biomarkers for BOS after lung transplantation which were explored in this study. The finding comes after comparing concentrations of various biomarkers in 33 adult HCT patients presenting with new-onset BOS, 31 HCT patients with non-BOS chronic GVHD, and 29 HCT patients with no history of chronic GVHD. Researchers observed that concentrations of the biomarker MMP-9 were higher in patients with BOS than in those without. Levels ≥200,000 pg/mL were associated with poorer overall survival in BOS patients. Investigators also found MMP-9 to be predictive of treatment response after fluticasone, azithromycin, and montelukast therapy for new-onset BOS cases, as concentrations of the plasma protein were elevated in patients who did not respond to the intervention. More research is needed, according to the study authors, to validate their results.

Read More

Tags: HCT, transplantation, Abstracts, cell therapy, Science, translational, newsletter, BOS, translational science, Allo HCT, Biomarker, response rate